

Performance in Delivering Research (PID) Q3 2018-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16/LO/2128	216431	PANORAMA: Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)	Number Agreed	50	50	31/03/2020	0	08/11/2017	0	Withdrawn By Sponsor	Closed early by sponsor due to changes in the scientific landscape and business priorities
16/NW/0275	204531	EMR100070-007 (JAVELIN) GASTRIC: A Phase III open-label, multicenter trial of maintenance therapy with Avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction	Number Agreed	5	5	25/11/2023	3	24/10/2017	3	Withdrawn By Sponsor	Closed by sponsor - sample size reached
15/LO/1818	190303	PASTOR: A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension	Number Agreed	5	5		1	07/11/2017	1	Withdrawn By Sponsor	Sponsor terminated early following sponsor portfolio review
11/LO/1915	92260	PACE - International Randomized Study of Laparoscopic Prostatectomy vs Robotic Radiosurgery and Conventionally Fractionated Radiotherapy vs Radiosurgery for Early Stage Organ-Confining Prostate Cancer	Number Agreed	10	10	26/04/2026	25	24/11/2017	25	Recruitment Finished	Target Achieved
11/NW/0782	82914	POUT - A Phase III randomised trial of PeriOperative chemotherapy versus sUrveillance in upper Tract urothelial cancer	Number Agreed	2	2	30/05/2017	5	10/11/2017	5	Recruitment Finished	Target Achieved
13/LO/1463	130983	InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease	Number Agreed	3	3	02/08/2018	2	15/11/2017	2	Recruitment Finished	Sponsor reached sample size
14/LO/2181	154300	RIO - Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer	Number Agreed	4	4		0	31/10/2017	0	Withdrawn By Sponsor	Sponsor closed the study early - lower than anticipated recruitment
15/NW/0917	190004	JAVELIN LUNG: A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non-small-cell lung cancer	Number Agreed	5	5	31/01/2017	1	07/08/2017	1	Recruitment Finished	Target not met due to rare patient group
15/SC/0291	178738	AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMOURS	Number Agreed	8	8	13/12/2019	2	08/12/2017	2	Withdrawn By Sponsor	Closed by sponsor - all cohorts full
15/YH/0388	182060	A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)	Number Agreed	2	2	30/08/2017	7	23/10/2017	7	Recruitment Finished	Target Achieved
13/LO/1375	135317	OvPSYCH 2: A randomised controlled trial to evaluate the impact of psychological support intervention after chemotherapy for women with ovarian cancer	Number Agreed	15	15	31/08/2017	6	31/10/2017	6	Recruitment Finished	Substantial delay from the Sponsor as the contracts were not correct. This impacted on our timelines for recruitment which meant we did not hit target.